Detalhe da pesquisa
1.
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Lancet Oncol
; 22(6): 883-892, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989559